LSD1 inhibition attenuates targeted therapy-induced lineage plasticity in BRAFV600E colorectal cancer DOI
Christopher A. Ladaika, Averi Chakraborty, Ashiq Masood

et al.

Published: Oct. 29, 2024

activating mutations occur in approximately 10% of metastatic colorectal cancer (CRCs) and are associated with worse prognosis due to an inferior response standard chemotherapy. Standard care for patients refractory

Language: Английский

Current and future directions in theranostics for neuroendocrine prostate cancer DOI
Gokce Belge Bilgin, Fabrice Lucien, Aadel A. Chaudhuri

et al.

Cancer Treatment Reviews, Journal Year: 2025, Volume and Issue: unknown, P. 102941 - 102941

Published: April 1, 2025

Language: Английский

Citations

0
Serotonin sets up neutrophil extracellular traps to promote neuroendocrine prostate cancer metastasis in the liver DOI Creative Commons
Dean G. Tang

Journal of Clinical Investigation, Journal Year: 2025, Volume and Issue: 135(8)

Published: April 14, 2025

Castration-resistant prostate cancer frequently metastasizes to the liver, and liver metastases often present a neuroendocrine phenotype (i.e., [NEPC]), but underlying molecular underpinnings remain unclear. In this issue of JCI, Liu et al. demonstrate that neurotransmitter serotonin (also known as 5-hydroxytryptamine), produced by NEPC cells, gained access activated neutrophils modifying histone 3 (H3) form neutrophil extracellular traps, which in turn promoted macrometastases liver. The study suggests blocking transport inhibiting enzymes catalyze serotonin-mediated H3 modifications may represent alternative approaches treating metastases.

Language: Английский

Citations

0
Immunohistochemical investigation of the transcription factor PROX1 emphasizing on neuroendocrine neoplasms DOI
Kuniaki Kojima, Kouhei Sakurai, Tatsuya Ando

et al.

Medical Molecular Morphology, Journal Year: 2025, Volume and Issue: unknown

Published: April 15, 2025

Language: Английский

Citations

0
LSD1 inhibition attenuates targeted therapy-induced lineage plasticity in BRAF mutant colorectal cancer DOI Creative Commons
Christopher A. Ladaika, Averi Chakraborty, Ashiq Masood

et al.

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: April 23, 2025

Abstract Background BRAF activating mutations occur in approximately 10% of metastatic colorectal cancer (CRCs) and are associated with worse prognosis part due to an inferior response standard chemotherapy. Standard care for patients refractory V600E CRC is treatment EGFR inhibitors recent FDA approval was given use these combination chemotherapy naïve CRC. Lineage plasticity neuroendocrine emerging mechanism targeted therapy resistance several types. Enteroendocrine cells (EECs), the cell intestine, uniquely present mutant as compared wildtype Methods plus inhibitor induced changes composition were determined by gene expression, imaging single approaches multiple models Furthermore, clinically relevant lysine demethylase LSD1 tested determine which blocked composition. Results Combined inhibition enriched EECs all tested. Additionally, other secretory types a subset patient samples following therapy. Importantly, attenuated therapy-induced EEC enrichment through blocking interaction LSD1, CoREST2 STAT3. Conclusions Our findings that induces lineage represents new paradigm how occurs. our finding blocks has potential improve responses patients.

Language: Английский

Citations

0
Bexarotene regulates zebrafish embryonic development by activating Wnt signaling pathway DOI

Wenwen Zha,

Ziang Wang,

Weitao Hu

et al.

Life Sciences, Journal Year: 2025, Volume and Issue: unknown, P. 123664 - 123664

Published: April 1, 2025

Language: Английский

Citations

0
LSD1 inhibition attenuates targeted therapy-induced lineage plasticity in BRAFV600E colorectal cancer DOI
Christopher A. Ladaika, Averi Chakraborty, Ashiq Masood

et al.

Published: Oct. 29, 2024

activating mutations occur in approximately 10% of metastatic colorectal cancer (CRCs) and are associated with worse prognosis due to an inferior response standard chemotherapy. Standard care for patients refractory

Language: Английский

Citations

0